STAT

APRIL 26, 2024

New federal rules aimed at limiting the spread of the H5N1 bird flu virus among dairy cattle go into effect Monday, but detailed guidance documents released Friday by the U.S. Department of Agriculture reveal its mandatory testing order is less stringent than initially described. While that is easing concerns from farmers and veterinarians about the economic and logistical burden of testing, it leaves questions about how effective the testing program will be at containing additional outbreaks.

Documentation 363

Documentation 363

PharmaVoice

APRIL 26, 2024

Dr. Jeremy Levin, CEO of Ovid Therapeutics, explains how scientific advances have converged to create a new era of drug development potential.

Drug Development 200

Drug Development 200

STAT

APRIL 26, 2024

On a spring afternoon in Tucson, Ariz., about a half dozen children and teens hung out in the sunny common room of Pima County’s Crisis Response Center. Beyond the pastel-painted room stretched a long, wide hall where partitions separated individual beds, many left unmade with rumpled sheets. Wearing scrubs, the kids sat in rocking chairs, watched TV, talked and laughed.

358

358

The Pharmacist

APRIL 26, 2024

Six in 10 independent pharmacy owners say that less than half of their Pharmacy First consultations pass the gateway point for a service payment, a survey has suggested. A majority of respondents said they were spending an average of 20 minutes or more on each consultation, according to the survey of 266 independent pharmacy owners […] The post Pharmacists spending time on unpaid Pharmacy First consultations, survey shows appeared first on The Pharmacist.

Independent Pharmacies 132

Independent Pharmacies 132

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

APRIL 26, 2024

Hospitals and health care systems across the United States have long been expected to provide patients with high-quality, cutting-edge care and outcomes — while staying cost-effective. Their shared mission is to continue to improve the care they provide their patients; their shared responsibility is to do so without increasing costs by shifting from fee-for-service to value-based care.

Hospitals 311

Hospitals 311

The Pharmacist

APRIL 26, 2024

A tool that calculates the carbon footprint of medicines has launched after being awarded £730,000 in funding through the Small Business Research Initiative (SBRI). Sustainable medicines company YewMaker has created the Medicines Carbon Footprint (MCF) formulary, a free tool which provides the per dose carbon footprints for over 4,000 medicines. Users can compare the medicine carbon […] The post Tool detailing carbon footprint of medicines launches appeared first on The Pharmacist.

128

128

pharmaphorum

APRIL 26, 2024

Explore the latest advancements and initiatives in kidney disease research, driving change for patients with kidney conditions. Learn more about the current research landscape and potential breakthroughs in treatment from Kidney Research UK.

125

125

STAT

APRIL 26, 2024

MultiPlan is facing a new class action lawsuit that alleges the company and large health insurers “conspired to fix, suppress, and stabilize” payments made for out-of-network medical claims. The lawsuit, filed by for-profit hospital company Allegiance Health Management, builds on the contentious relationship between hospitals and MultiPlan, a data technology vendor that works with the biggest insurers to determine how much should be paid for care that is delivered outside of an ins

Hospitals 278

Hospitals 278

pharmaphorum

APRIL 26, 2024

Owlstone Medical has secured a $5 million equity investment and initial $1.5 million grant funding, committed by the Bill and Melinda Gates Foundation, for development of breath-based diagnostic solutions to improve outcomes in the developing world.

115

115

STAT

APRIL 26, 2024

WASHINGTON — A House committee next month plans to mark up legislation that would restrict U.S. biotechnology companies from doing business with a Chinese company that makes key drug ingredients, according to five lobbyists tracking the BIOSECURE Act. The goal is for the House to pass the bill before the July 4 recess, setting it up to be included in a year-end must-pass legislative package.

Packaging 275

Packaging 275

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

BioPharma Dive

APRIL 26, 2024

The Food and Drug Administration approval of Beqvez comes as other gene therapies for the bleeding condition that were approved earlier struggle to gain traction.

116

116

STAT

APRIL 26, 2024

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is likely to be low key. We plan to manicure the Pharmalot grounds, promenade with the official mascots, and catch up on our napping. We may also hold a listening party, where the rotation may include this , this , this and this.

Biosimilars 274

Biosimilars Specialty Pharmacies Hospitals 274

pharmaphorum

APRIL 26, 2024

In an ambitious move, Moderna has teamed up with OpenAI, the artificial intelligence company behind ChatGPT, to further integrate generative AI (GenAI) across its mRNA drug development and manufacturing operations.

Drug Development 110

Drug Development 110

STAT

APRIL 26, 2024

It’s another busy day in my spine surgery clinic when my phone rings. Patients are waiting, but I’d be unwise to put off the caller: a physician calling from a health insurance company. This peer-to-peer call is part of the prior authorization process; my “peer” needs information to determine whether the company will cover a procedure I requested for one of my patients.

Health Insurance Companies 270

Health Insurance Companies 270

The Pharmacist

APRIL 26, 2024

Just one IT provider is believed to have rolled out updates to allow pharmacies to send structured records of Pharmacy First consultations to GP practices, The Pharmacist understands. At the time of writing Cegedim Rx was understood to be the only supplier to have gone live with GP Connect's Update Record integration so far, despite […] The post Just one pharmacy IT supplier has enabled integrated Pharmacy First GP updates appeared first on The Pharmacist.

105

105

STAT

APRIL 26, 2024

Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person each week.

230

230

Express Pharma

APRIL 26, 2024

Under the collaboration, Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform (AIP) to further power its clinical data platform, focused on driving clinical trial efficiency while maintaining the safety and regulatory rigor Parexel and Palantir Technologies has announced a multi-year strategic partnership to leverage AI to help enhance and accelerate the delivery of safe and effective clinical trials for the world’s biopharma customers.

Drug Development 105

Drug Development 105

pharmaphorum

APRIL 26, 2024

Chemists at ETH Zurich have developed a new computer process that enables the generation of active pharmaceutical ingredients at speed, based on a protein’s three-dimensional surface.

104

104

European Pharmaceutical Review

APRIL 26, 2024

A paper has reported the first time that 3D printing has facilitated two active pharmaceutical ingredients (APIs) to be combined in the same formulation. This method enables the number of administrations of the drug evaluated to be minimised, the researchers found. The authors aimed to evaluate and compare the efficacy and acceptability of chewable 3D printed medicines containing citrulline, isoleucine, and valine alone or in combination.

Compounding 93

Compounding Hospitals 93

Outsourcing Pharma

APRIL 26, 2024

In an extensive and enlightening chat with Prasad Rajeev, the CEO of LGM Pharma, OSP gained profound insights into the company's trajectory within the pharmaceutical industry.

89

89

European Pharmaceutical Review

APRIL 26, 2024

“approval [of Pyzchiva ® (biosimilar ustekinumab)] of is a crucial step towards offering European patients an additional safe and effective treatment option” Pharmaceutical company Sandoz has announced that the European Commission (EC) has granted marketing authorisation for Pyzchiva ® (biosimilar ustekinumab ). Pyzchiva was developed and registered by Samsung Bioepis to match the reference medicine.

Biosimilars 84

Biosimilars Packaging Pharmaceutical Companies Pharmaceutical Companies 84

Pharma Times

APRIL 26, 2024

The paper identifies the roles of LARP4A and LARP4B in sarcoma and carcinoma cancers

113

113

European Pharmaceutical Review

APRIL 26, 2024

AbbVie has revealed positive topline results from the first head-to-head trial in atopic dermatitis assessing RINVOQ ® (upadacitinib) at a starting dose of 15mg daily versus DUPIXENT ® ( dupilumab ) at its labelled dose. The Phase IIIb/IV LEVEL UP study evaluated the efficacy and safety of these drugs in individuals 12 years old and older with moderate-to-severe atopic dermatitis.

Labelling 83

Labelling 83

World Pharma News

APRIL 26, 2024

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved BEQVEZ™ (fidanacogene elaparvovec-dzkt) for the treatment of adults with moderate to severe hemophilia B who currently use factor IX (FIX) prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes, and do not have neutralizing antibodies to adeno-associated virus serotype Rh74var (AAVRh74var) capsid as detected by an F

74

74

Pharma Times

APRIL 26, 2024

The new method could help to prevent severe side effects caused by enantiomer drugs

101

101

Big Molecule Watch

APRIL 26, 2024

On April 23, 2024, Alvotech announced “positive topline results from a confirmatory clinical study for AVT05,” Alvotech’s proposed golimumab biosimilar to Janssen Biotech, Inc.’s SIMPONI (R) and SIMPONI ARIA (R). According to Alvotech, the confirmatory clinical study (NCT05842213) was a randomized, double-blind, two-arm, multicenter clinical study designed to investigate the therapeutic equivalency of AVT05 and SIMPONI (R) for the treatment of rheumatoid arthritis.

Biosimilars 70

Biosimilars 70

pharmaphorum

APRIL 26, 2024

Merino Perugini from Nestlé Health Science sat down for an exclusive interview with Jonah Comstock from Reuters Pharma USA to discuss the company's latest innovations and successes in the healthcare industry. Get insights into their strategies and future plans.

71

71

Drug Channels

APRIL 26, 2024

Today’s guest post comes from Kevin Kettler, President of CoverMyMeds. Kevin asks: What if there were no barriers across the therapy access and reimbursement process? In his view, eliminating barriers requires a combination of expert insight, actionable data, and simplification of the providers' experiences. Click here to learn more about CoverMyMeds’ comprehensive technology solutions.

70

70

PharmaTech

APRIL 26, 2024

As breakthrough therapeutics in the pharma pipeline approach commercialization, pharmaceutical manufacturing facilities must evolve to meet demand.

Pharmaceutical Manufacturing 72

Pharmaceutical Manufacturing 72

Pharmafile

APRIL 26, 2024

ANGLE has announced that it has signed a supplier agreement with AstraZeneca for the development and validation of a methodology which will leverage ANGLE’s existing DNA damage response (DDR) assay for the detection of micronuclei in circulating tumour cells (CTCs) as a measure of DDR. The post ANGLE signs commercial agreement with AstraZeneca appeared first on Pharmafile.

63

63

Drug Patent Watch

APRIL 26, 2024

Annual Drug Patent Expirations for DROSPIRENONE Drospirenone is a drug marketed by Exeltis Usa Inc, Barr, Glenmark Pharms Ltd, Hetero Labs, Hlthcare, Jubilant Cadista, Mylan Labs Ltd, Watson Labs, Apotex,… Source

59

59

Pharmafile

APRIL 26, 2024

Regeneron Pharmaceuticals and Mammoth Biosciences have announced a collaboration for the research, development and commercialisation of in vivo CRISPR-based gene editing therapies for multiple tissue and cell types. The post Regeneron and Mammoth Biosciences announce CRISPR collaboration appeared first on Pharmafile.

63

63

Pharmaceutical Business Review

APRIL 26, 2024

As part of the new collaboration , the two companies will work together to co-c reate the candidate for the oncology target, leveraging PepMetics technology. Once the development candidate is identified, PRISM BioLab will license its rights to Ono , which will then facilitate the further clinical development and commerciali s ation efforts. T he agreement includes upfront payments, as well as milestone payments based on the success of pre-clinical, clinical, and commercialisation efforts.

59

59

BioPharma Dive

APRIL 26, 2024

Prescription volume erosion is tracking with company forecasts, executives claimed, even as more insurers could exclude the branded drug.

Biosimilars 68

Biosimilars 68

Drug Patent Watch

APRIL 26, 2024

Annual Drug Patent Expirations for OXYCONTIN Oxycontin is a drug marketed by Purdue Pharma Lp and is included in one NDA. It is available from three suppliers.

59

59